This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona on August 26, 2017
The educational objectives of this symposium were to:
- To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
- To understand the origin of the high residual cardiovascular risk in patients with diabetes, ACS
- To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD
- To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management
Kausik Ray, MD, is cardiologist, and Professor of Public Health/Honorary Consultant Cardiologist at Imperial College London, United Kingdom
This symposum was supported by an unrestricted educational grant provided by ResverlogixThe information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- Managing Diabetes & CVD: Is epigenetics a new way forward?Insights from the first trials in epigenetics in human: What is the way forward?
Stephen Nicholls, MD
- Managing Diabetes & CVD: Is epigenetics a new way forward?Promise of epigenetic modulation as a target in atherosclerotic patients
Erik SG Stroes, MD